Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Still, every patient responds differently
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
:max_bytes(150000):strip_icc()/Health-GettyImages-2190382180-5fb9712447fa4ce29876665304bbe000.jpg)
Optimum SmoothFlow pistons come in a variety of styles to optimize each unique dispensing process
Some preliminary animal studies and limited human research have explored whether allulose consumption might indirectly influence incretin hormone secretion, including GLP-1
At Stellar Performance Medical, we view weight loss as a component of total body health
US$ 26.64
US$ 25.32
US$ 22.66
US$ 25.03
US$ 24.90
US$ 20.31
US$ 27.74
US$ 28.87
US$ 24.50
